Drugs.com - Monthly Update June 2025

Описание: This is the June 2025 edition of the Drugs.com Monthly Update. We cover five significant FDA approvals that are transforming patient care across multiple therapeutic areas.

• Dupixent (https://www.drugs.com/dupixent.html) (dupilumab), newly approved for treating bullous pemphigoid in adults—a painful autoimmune skin disorder primarily affecting patients over 65.
• Mavyret (https://www.drugs.com/mavyret.html) (glecaprevir/pibrentasvir) for acute hepatitis C virus treatment in children as young as 3 years old.
• Yeztugo (https://www.drugs.com/yeztugo.html) (lenacapavir), a groundbreaking twice-yearly injectable HIV prevention therapy offering a 99.9% effectiveness rate in clinical trials.
• Enflonsia (https://www.drugs.com/enflonsia.html) (clesrovimab-cfor), a new RSV prevention option for neonates and infants that provides season-long protection with a single injection.
• Ibtrozi (https://www.drugs.com/ibtrozi.html) (taletrectinib), an oral targeted therapy approved for ROS1-positive non-small cell lung cancer in patients with locally advanced or metastatic disease.

Chapters:


• (00:00) - Intro


• (00:24) - Overview


• (00:45) - Dupixent


• (01:38) - Mavyret


• (02:14) - Yeztugo


• (03:14) - Enflonsia


• (03:54) - Ibtrozi


• (04:26) - Outro


Follow Drugs.com:
• X (  / drugscom  ) , Facebook (  / drugscom  ) , Youtube (   / drugscom  )
• Signup to our newsletters (https://www.drugs.com/newsletters/)
• Download the app (https://www.drugs.com/apps/)